Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02204982
Title Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

non-Hodgkin lymphoma

Therapies

Duvelisib

Rituximab

Age Groups: adult
Covered Countries


No variant requirements are available.